LSKB Announces Enrollment of the First Patient in its Apatinib-Nivolumab Combination Study
SALT LAKE CITY, USA, December 27, 2017 — LSK BioPharma (LSKB, Company) announced that it has enrolled the first patient in a clinical trial studying the combination of apatinib with the immuno-oncology drug nivolumab. This study (designated LSK-AM107) is an open-labeled, single-center, Phase 1 study designed to evaluate the safety, tolerability, and efficacy of adding apatinib to ongoing nivolumab treatment in patients with unresectable or metastatic cancer. The study is taking place at the Cancer Center of Southern California (CCSC) under the direction of Dr. Sant P. Chawla.
“I-O (immuno-oncology) has proven to be a promising tool in treating many cancers,” said Dr. Sung Chul Kim, President, “Based on preclinical studies, we believe that combining I-O with apatinib will make the therapy available to a wider population of cancer patients.”
LSKB is also planning to support an Investigator Initiated Trial (IIT) at a US institution studying the safety and efficacy of apatinib in combination with pembrolizumab. This study is expected to enroll its first patients in early 2018.
About Apatinib
Apatinib is the first successful small-molecule angiogenesis inhibitor in gastric cancer. Apatinib acts by inhibiting angiogenesis, a critical process in cancer growth and proliferation. Specifically, apatinib selectively inhibits VEGFR-2 which mediates the primary pathway for tumor-mediated angiogenesis. It was approved in China (advanced gastric cancer, Dec 2014) where it is marketed by the Chinese-territory license-holder Jiangsu Hengrui Medicine Co., Ltd. LSK BioPharma, which holds the global rights (ex-China), has partnered development and marketing in South Korea with Bukwang Pharmaceutical Co., Ltd. The Company is currently conducting a global (12 countries including US, Japan, Korea, Italy, Germany, and Russia) Phase 3 clinical trial of apatinib in advanced or metastatic gastric cancer patients. Apatinib has been clinically tested in over 1,000 patients worldwide and has demonstrated efficacy in numerous cancers including gastric cancer, CRC, HCC, NSCLC, esophageal cancer, thyroid cancer, mesothelioma, and neuroendocrine tumors. It has also shown potential to significantly improve outcomes in combination with chemotherapeutics and immunotherapy, as well as for maintenance therapy. LSKB has received notification designating apatinib as an orphan medicinal product for the treatment of gastric cancer from the European Commission in the European Union, the US FDA, as well as the MFDS in South Korea.
About CCSC and SORC
The Cancer Center of Southern California (CCSC) and Sarcoma Oncology Research Center (SORC) is a fully integrated cancer treatment and clinical research center, led by Founder and Director, Sant P. Chawla, MD, FRACP. Dr. Chawla is a recognized leader in the field of sarcoma and oncology, combining FDA approved treatments with emerging investigational medicine via clinical trials, for optimal patient care. The SORC specializes in trials for rare sarcomas, solid tumors and phase 1 research. As a private research institution, SORC/CCSC delivers highly personalized care and offers expanded treatment options for patients through research based treatments, as clinically indicated. Dr. Chawla has conducted clinical research for more than 30 years, making key contributions to many clinical development programs.
About LSK BioPharma
LSKB is a privately-held biopharmaceutical company based in Salt Lake City, Utah. The Company specializes in clinical development of promising targeted therapies for unmet medical needs in cancer. LSKB is developing two proprietary drug candidates; apatinib, a selective VEGFR-2 inhibitor which has demonstrated clinical efficacy in a variety of solid tumors and a selective BTK/JAK3 inhibitor (designated LSK9985) with the potential to treat hematologic malignancies and rheumatoid arthritis as an immunosuppressive agent. LSKB can be found on the web at www.lskbiopharma.com.
Contact:
Angie Price
angieprice@lskbiopharma.com
###
